Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CGON vs FDMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CGON Captures Overall Composite Edge (45.0 HOLD vs 51.3 HOLD), While FDMT Leads 3–2 on Growth & Valuation Pillars

CGON Overall Winner 6-Pillar Tally: CGON 2 – 3 FDMT (1 Tie) Matrix Metrics: CGON 5 – 3 FDMT

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (45.0/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. CGON trades at $84.94 (N/M Forward P/E, -4293.5% operating margin) versus FDMT at $11.41 (N/M Forward P/E, -222.7% operating margin).

  • Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -222.7% operating margin) and revenue trajectory (-3.7% vs. +4505.6% YoY).
  • Technical & Structure Timing Caution: CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CGON vs FDMT
CGON NASDAQ Head-to-Head Winner
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap $6.3B
TTM Revenue $6.2M
Forward P/E N/M
Beta / 30D Vol 0.77β · 86% Vol
Unified Composite Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 72
RSI-14: 71.7 · SMA20: $67.45 · SMA50: $68.25
FDMT NASDAQ
4D Molecular Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$11.41
-6.7% 1D
Market Cap $669.3M
TTM Revenue $96M
Forward P/E N/M
Beta / 30D Vol 1.90β · 91% Vol
Unified Composite Score
51.3 / 100 HOLD
Tech 51.0 Fund 47.0 Flow 66.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.3%), weak momentum, RSI 45
RSI-14: 44.9 · SMA20: $12.10 · SMA50: $13.07

6-Pillar Scorecard Institutional Category Breakdown (CGON 2 – 3 FDMT)

Columns: Metric · CGON · FDMT
1. Valuation Multiples FDMT
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 6.6x
2. Growth & Scale FDMT
Revenue Growth (YoY) -3.7% +4505.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.2M $96M
Market Cap $6.3B $669.3M
3. Profitability & Quality CGON
Gross Margin N/A N/A
Operating Margin -4293.5% -222.7%
Net Profit Margin 0.0% -208.6%
Return on Equity (ROE) -28.3% -56.7%
4. Balance Sheet & Cash Flow FDMT
Cash Generation (TTM) -$189M -$156M
Cash Flow Margin N/A N/A
Net Cash / Leverage $19M Net Cash $31M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CGON
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 238.6% (85th %ile) 82.4% (10th %ile)
Put/Call OI Skew 0.35x (Call-Skewed) 5.16x (Put-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CGON (5) vs FDMT (3)
Institutional Metric CGON FDMT Criterion Row Edge
Market Capitalization
Scale
$6.3B $669.3M Larger Scale CGON
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-3.7% +4505.6% Higher Growth FDMT
Operating Margin (TTM)
Profitability
-4293.5% -222.7% Higher Margin FDMT
Net Profit Margin
Profitability
0.0% -208.6% Higher Margin CGON
Return on Equity (ROE)
Capital Efficiency
-28.3% -56.7% Higher ROE CGON
52-Week Range Position
Momentum
84% ($37–$94) 45% ($7–$17) Stronger Trend CGON
Beta / 30D Volatility
Risk Regime
0.77β · 86% Vol 1.90β · 91% Vol Lower Realized Risk CGON
Unified Institutional Score
Composite Signal
45.0 / 100 (HOLD) 51.3 / 100 (HOLD) Higher Composite FDMT
Trailing 12M Revenue (USD)
Operating Scale
$6.2M $96M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 6.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$189M ($19M Net Cash) -$156M ($31M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CGON +47.92 pp
CGON: +41.91% · FDMT: -6.01%
3M Horizon CGON +33.82 pp
CGON: +11.33% · FDMT: -22.49%
6M Horizon FDMT +1.43 pp
CGON: +34.97% · FDMT: +36.4%
1Y Horizon CGON +113.94 pp
CGON: +124.93% · FDMT: +10.99%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period CGON Revenue FDMT Revenue CGON Op. Margin FDMT Op. Margin Margin Leader
FY2019 N/A $10M N/A -729.4% FDMT
FY2020 N/A $10M N/A -424.0% FDMT
FY2021 N/A $20M N/A -395.5% FDMT
FY2022 N/A $0M N/A -3516.5% FDMT
FY2023 $0M $20M -27180.9% -544.6% FDMT
FY2024 $0M $0M -10067.3% -507678.4% CGON
FY2025 $0M $90M -4722.1% -187.2% FDMT

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CGON CONSOLIDATION
62d in phase · OBV ACCUMULATION
Current IV 238.6%
IV Percentile 85th %ile
Put/Call OI Skew 0.35x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CGON Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FDMT BREAKDOWN
62d in phase · OBV NEUTRAL
Current IV 82.4%
IV Percentile 10th %ile
Put/Call OI Skew 5.16x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CGON Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $6.3B market capitalization and -4293.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FDMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $669.3M market capitalization and -222.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CGON vs FDMT Key Questions & Quantitative Answers

As of Nov 16, 2026, CG Oncology, Inc. (CGON) captures the overall head-to-head institutional edge over 4D Molecular Therapeutics, Inc. (FDMT) on higher Unified Composite conviction (45.0/100 HOLD vs. 51.3/100 HOLD) after splitting the core matrix 5–3 (led by Profitability & Quality, Options & Positioning), while FDMT wins 3–2 across the 6-pillar growth and valuation breakdown. CGON trades at $84.94 (N/M Forward P/E, -4293.5% operating margin) versus FDMT at $11.41 (N/M Forward P/E, -222.7% operating margin). Composite vs. Pillar Nuance: While FDMT currently prints a higher short-term Unified Composite Score (51.3/100 HOLD vs. CGON 45.0/100 HOLD), CGON captures the overall institutional head-to-head verdict (5–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-4293.5% vs. -222.7% operating margin) and revenue trajectory (-3.7% vs. +4505.6% YoY). Technical & Structure Timing Caution: CGON trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 71.7); meanwhile FDMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FDMT leads the Growth & Scale pillar: CGON posts -3.7% YoY revenue growth and +0.0% YoY earnings growth on $6.2M TTM revenue (N/A gross margin, -4293.5% operating margin), compared with FDMT at +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), CGON cumulative revenue shifted N/A while FDMT shifted +800.0%. In operating R&D and SG&A reinvestment, CGON deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FDMT.

FDMT screens cheaper on headline valuation multiples. CGON trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CGON (-28.3% ROE) versus FDMT (-56.7% ROE) capital efficiency.

In options market volatility and institutional positioning, CGON carries 238.6% implied volatility (85th %ile, Extreme (>80th %ile)), a 0.35x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.77β · 86% Vol realized risk). By comparison, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.90β · 91% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.